NurExone Biologic Inc.

OTC: NRXBF · Healthcare · Biotechnology

Canadian filerHQ Toronto, ONReports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 31

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

as of 2026-08-03

Market cap

$22.8M

as of 2026-08-03

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is NurExone Biologic Inc.’s financial profile?

NurExone Biologic Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

HeartBeam, Inc.——Tevogen Bio Holdings Inc.——Actuate Therapeutics Inc——Quantum BioPharma Ltd.——Werewolf Therapeutics, Inc.——Cellectar Biosciences, Inc.——

Key facts

CEOLior Shaltiel

SectorHealthcare

IndustryBiotechnology

HeadquartersToronto, ON

ExchangeOTC: NRXBF

Employees16

IPO date2023-11-10

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.